NCT04362176
Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults
PHASE3
COMPLETED
NCT04362176
INTERVENTIONAL
Passive Immunity Trial for Our Nation (PassItOn)
The purpose of this study is to test the safety and efficacy of convalescent donor plasma to treat COVID-19 in hospitalized adults in a randomized, placebo-controlled setting. The effect of convalescent plasma will be compared to placebo on clinical outcomes, measured using the COVID-19 7-point Ordinal Clinical Progression Outcomes Scale at Day 15, among adults with COVID-19 requiring hospitalization.
Inclusion Criteria:
1. Age greater than or equal to 18 years
2. Currently hospitalized or in an emergency department with anticipated hospitalization
3. Symptoms of acute respiratory infection, defined as one or more of the following:
1. Cough
2. Chills, or a fever (greater than 37.5° C or 99.5° F)
3. Shortness of breath, operationalized as a patient having any of the following:
i. Subjective shortness of breath reported by a patient or surrogate. ii. Tachypnea with respiratory rate of greater than 22 breaths per minute iii. Hypoxemia, defined as SpO2 less than 92% on room air, new receipt of supplemental oxygen to maintain SpO2 greater than or equal to 92%, or increased supplemental oxygen to maintain SpO2 greater than or equal to 92% for a patient on chronic oxygen therapy
4. Laboratory-confirmed SARS-CoV-2 infection within the past 14 days
Exclusion Criteria:
1. Prisoner
2. Unable to randomize within 14 days after onset of acute respiratory infection symptoms
3. Patient, legal representative, or physician not committed to full support (Exception: a patient who will receive all supportive care except for attempts at resuscitation from cardiac arrest will not be excluded.)
4. Inability to be contacted on Day 29-36 for clinical outcome assessment
5. Receipt of any SARS-CoV-2 passive immunity therapy, such as convalescent plasma, monoclonal antibodies, or pooled immunoglobulin, in the past 30 days
6. Contraindications to transfusion or history of prior reactions to transfused blood products
7. Plan for hospital discharge within 24 hours of enrollment
8. Previous enrollment in this trial
9. Previous laboratory-confirmed SARS-CoV-2 infection before the current illness
10. Enrollment in another clinical trial evaluating monoclonal antibodies, convalescent plasma, or another passive immunity therapy
11. Prior receipt of SARS-CoV-2 vaccine
COVID-19
Coronavirus
SARS-CoV-2
- TREATMENT
-
- Type: BIOLOGICAL
- Name: pathogen reduced SARS-CoV-2 convalescent plasma
- Description: Convalescent COVID-19 donor plasma is the liquid part of blood that is collected from patients who have recovered from COVID-19 infection. This plasma contains SARS-CoV-2 specific antibodies that may help fight the infection.
- Arm Group Labels: pathogen reduced SARS-CoV-2 convalescent plasma
-
- Type: BIOLOGICAL
- Name: Placebo
- Description: Lactated Ringer's solution with multivitamins
- Arm Group Labels: Placebo
- Vanderbilt University Medical Center